Dr. Mark Pollack is Director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, and Professor of Psychiatry at Harvard Medical School. He received his medical degree in 1982 from New Jersey Medical School, and completed residency and fellowship training in psychiatry at Massachusetts General Hospital.
Dr. Pollack has received federal funding from the National Institute of Mental Health (NIMH) and National Institute of Drug Abuse (NIDA) to study the longitudinal course of panic disorder, the application of cognitive-behavioral intervention of benzodiazepine discontinuation in panic disorder patients to the reduction of illicit drug use in drug abusers, the impact of recent terrorist attacks on the development of PTSD and course of disorder in bipolar patients, changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance, and treatment response and pharmacogenetics in refractory social anxiety disorder, and the use of d-cycloserine to enhance the treatment efficacy of cognitive-behavioral therapy in social anxiety disorder.
He has published over 300 articles, reviews and chapters, and is co-editor of the books Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies, Panic Disorder and its Treatment, and Social Phobia: Research and Practice. Dr. Pollack is editor-in-chief of the journal CNS Neuroscience and Therapeutics, lectures widely in national and international forums, serves on numerous editorial and advisory boards, as well as the Scientific Advisory Board of the Anxiety Disorders Association of America and the Board of Directors of the Mood and Anxiety Disorders Institute of the Massachusetts General Hospital.
His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.
Pfizer, AstraZeneca, Sepracor, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Roche Laboratories, UCB Pharma, Wyeth, Cyberonics, NARSAD, NIDA, NIMH, Cephalon, and Forest.
Pfizer, Solvay, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Wyeth, and Forest.
BrainCells Inc, Dov Pharma, Jazz Pharma, MedAvante, Neurocrine, Neurogen, Novartis, Otsuka Pharma, Pfizer, AstraZeneca, Sanofi, Sepracor, Solvay, Tikvah Therapeutics, Transcept Inc, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Roche Laboratories, UCB Pharma, Wyeth, Cephalon, Forest, and Predix.
MedAvante and Mensante Corp.
SIGH-A and SAFER
Last updated: 7/27/2010